<DOC>
	<DOC>NCT02150720</DOC>
	<brief_summary>The main hypothesis of this clinical trial is that the use of intra-articular tranexamic acid and the fibrin glue plus usual hemostasis will reduce at least a 25% the postoperative blood loss with respect to usual hemostasis in patients undergoing subcapital femoral fractures.</brief_summary>
	<brief_title>Prevention of Postoperative Bleeding in Subcapital Femoral Fractures</brief_title>
	<detailed_description />
	<mesh_term>Fractures, Bone</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Femoral Fractures</mesh_term>
	<mesh_term>Postoperative Hemorrhage</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Patients over 18 years Patients with unilateral subcapital femoral fracture Patients requiring hip replacement (total or partial) Signed informed consent from the patient or legal representative Known allergy to fibrin glue and tranexamic acid Multiple fractures Pathological fractures Contraceptives or estrogen therapy Use of blood salvage during surgery History compatible with thromboembolic disease: Cerebral vascular accident Ischemic heart disease (myocardial infarction, angina ) Deep vein thrombosis Pulmonary Embolism Peripheral arterial vasculopathy Patients with thrombogenic arrhythmias Patients with cardiovascular stents Prothrombotic alterations in coagulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hip fractures</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Randomized</keyword>
	<keyword>Fibrin glue</keyword>
	<keyword>Tranexamic acid</keyword>
	<keyword>Blood loss</keyword>
</DOC>